• Lonza adds new Nebula® Absorbance Reader to its portfolio of Lonza-developed and optimized microplate readers for streamlined endotoxin and pyrogen testing
• The instrument is fully integrated with Lonza’s latest WinKQCL® Software to enable data integrity compliance, streamline training, and reduce validation burden
• The optimized reader offers premium performance when used in combination with Lonza reagents

Today, Lonza has launched the Nebula® Absorbance Reader, a new absorbance microplate reader which joins the company’s portfolio of optimized instruments for streamlined endotoxin and pyrogen testing.

Pharmaceutical quality control (QC) laboratories worldwide rely on the traditional absorbance-based Limulus amebocyte lysate (LAL) and Tachypleus amebocyte lysate (TAL) assays to assure the safety of raw materials in-process samples and manufactured products. However, the industry-standard absorbance reader for these assays — the ELx808™ Absorbance Microplate Reader (ELx808™) — will no longer be sold by Lonza from late 2023. The Nebula® Absorbance Reader represents a technologically advanced, high-performance replacement reader, which delivers results comparable to those typically found with ELx808™ and will facilitate the smooth continuation of current pyrogen and endotoxin testing programs.

Similar to the Nebula® Multimode Reader, the Nebula® Absorbance Reader is designed for use alongside Lonza reagents. It is optimized to work with, and meet all the specifications of, Lonza’s absorbance-based endotoxin assays such as the Lonza PYROGENT® 5000 Turbidimetric and  Kinetic-QCL® Chromogenic Endotoxin Assays. The new reader also supports the readout for monocyte activation tests (MAT) such as Lonza’s PyroCell® MAT System.

The Nebula® Absorbance Reader provides QC labs with new and improved functionality. It features high-performance optics and monochromator-based wavelength selection to enable precise and accurate measurements of endotoxin levels. Its compact design requires minimal laboratory space and allows for workflow flexibility.

The reader is fully integrated with the latest version of Lonza’s WinKQCL® Endotoxin Detection and Analysis Software (v6.4), enabling users to meet the latest data integrity requirements. This reduces training burdens by removing the need for existing WinKQCL® Software users to learn new software in order to use the new reader. In addition, the Nebula® Absorbance Reader is similar in design and build to the Nebula® Multimode Reader – using the same user manual, service tools, and similar qualification procedures – which simplifies system maintenance.

Orla Cloak, Vice President, Head of Bioprocessing, Lonza, commented: “As we developed the new Nebula® Absorbance Reader, we focused on optimizing functionality to enable it to provide the very best results for our customers. QC teams can now access a thoroughly tested absorbance reader, specifically optimized for use with Lonza reagents and fully integrated with our WinKQCL® Software. This launch will allow customers to confidently continue endotoxin workflows in the same smooth and streamlined way they are used to, with the support of new and improved testing functionality.”

Lonza will present data from the Nebula® Absorbance Reader used with Lonza endotoxin assays during a poster presentation at the 2023 PDA Pharmaceutical Microbiology Conference in Washington, DC (US) from 2–4 October 2023.

Additional Information 
For more information on the Nebula® Absorbance Reader, please visit:  
www.lonza.com/absorbance-nebula

Disclaimer

Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this media advisory due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza, and are registered in USA, EU or CH or belong to third party owners and are used only for informational purposes.